2017 Executive Sponsor
2017 Supporting Partners
2017 Media Partners
2016 Executive Sponsors
Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development and commercialization. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Learn more at www.definiens.com.
NanoString Technologies provides life science tools for translational research and molecular diagnostics. nCounter® digital molecular barcoding enables simultaneous measurement of hundreds of genes, miRNAs, proteins, or copy number variations. Precise and highly sensitive, this technology facilitates numerous applications including NanoString’s first diagnostic product, the Prosigna® Prognostic Breast Cancer Gene Signature Assay. Learn more at www.nanostring.com.
2016 Associate Sponsors
BioLegend develops and manufactures world-class, cutting-edge antibodies and reagents at an outstanding value. The broad product portfolio includes flow cytometry, cell biology, and functional reagents for research in immunology, neuroscience, cancer, and stem cells. Custom services include assay development, sample testing, and conjugation. BioLegend is certified for ISO 9001:2008 and ISO 13485:2003. Learn more at www.biolegend.com
Crown Bioscience is a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research. CrownBio’s comprehensive offering of in vitro and in vivo models, and proven expertise in testing compounds efficacy and pharmacological profile guide research from initial drug discovery to clinical applications. Visit www.crownbio.com
Nilogen Oncosystems is dedicated to streamlining and improving cancer drug development in its CLIA-certified laboratory. Using its unique drug testing platforms that utilize fresh patient tumor tissue, Nilogen is able to assess the therapeutic potential of cancer drugs, including immunotherapeutics, significantly reducing the cost and risk associated with clinical trials. Learn more at www.nilogen.com.
2016 Supporting Sponsor
Neon was founded by Third Rock Ventures, recently raised a Series A of $55M, and is focused on developing next-generation vaccine and T cell therapies leveraging neoantigen biology. Neon’s lead program is a Phase 1 personalized neoantigen vaccine that builds upon R&D from the Broad Institute and Dana-Farber Cancer Institute. Visit www.neontherapeutics.com.
Personalis, Inc. provides clinical trials researchers with neoantigen identification for immuno-oncology with ACE ImmunoID™. Our ACE (Accuracy and Content Enhanced) Exome and ACE Transcriptome supplement coverage of over 8,000 biomedically important genes, including over 1,600 cancer-related genes, enabling identification of variants more accurately and reliably in difficult-to-sequence regions. Visit www.personalis.com.